The administrative law judge who determined a crucial Kodak digital photograph patent is invalid contradicted prior findings by another ITC judge and PTO re-examiners. The full commission said Friday that it wants to take a look at that discrepancy.

Reed Smith accused Sidley and McKool's client, Allcare, of flagrant patent trolling, and a Fort Worth judge agreed, holding the firms responsible for Allcare's missteps. But on reconsideration, he softened his view of the firms' role.

A federal judge in Riverside, Calif., ruled Wednesday that the heirs of Superman cocreator Jerry Siegel are co-owners of copyrights to the first two weeks of Superman daily newspaper strips and other early Superman material. The ruling is the latest in an ongoing dispute between the heirs and DC Comics and Warner Brothers.

There are no fewer than 43 amicus briefs already on file in the case that will determine the standard for business method patents. And the folks on the government's side are yet to chime in.

We've reported in piecemeal fashion about GE's patent infringement litigation campaign against its rival in the wind turbine market. But Mitsubishi is alleging there's nothing piecemeal about GE's conduct: It now claims GE first lied to the PTO to get its wind turbine patents, then deployed those fraudulent patents in a scheme to drive Mitsubishi out of the market.

All of a sudden, everything's coming up Rambus in its long-running litigation against the chip industry. But Nvidia says it will keep on fighting.

After a seven-day trial, a federal jury in Dallas ruled that Mitsubishi Heavy Industries had infringed one of GE's wind turbine patents and awarded $170 million in lost profits and royalties. This is GE's second court victory in two weeks involving wind turbine patents.

Microsoft seriously doesn't like to lose. So after failing in its first attempt to persuade the Federal Circuit to overturn the $290 million judgment against it, the software giant is rolling out Ted Olson and Thomas Hungar to help change the appellate court's view.

In August 2000, the New York Stock Exchange had to halt trading in shares of Eli Lilly after the Federal Circuit found its Prozac patent invalid for double-patenting. Ten years later, Winston & Strawn has hit Lilly with another double-patenting ruling, this time for a cancer drug. But there's a twist: The generic that won at the Federal Circuit won't be the first to bring its version of Lilly's drug to market.